Mozenavir (DMP-450) is an
antiviral drug which was developed as a treatment for
HIV/AIDS. It acts as an HIV
protease inhibitor and binds to this target with high affinity,[1][2] however despite promising results in early testing,[3][4] mozenavir was unsuccessful in human
clinical trials. Studies continue into related derivatives.[5]
References
^Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, et al. (May 1996). "Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors". Journal of Medicinal Chemistry. 39 (11): 2156–69.
doi:
10.1021/jm960083n.
PMID8667359.
^Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP (April 1998). "The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues". Bioorganic & Medicinal Chemistry Letters. 8 (7): 823–8.
doi:
10.1016/s0960-894x(98)00119-x.
PMID9871548.
^De Clercq E (April 2002). "Highlights in the development of new antiviral agents". Mini Reviews in Medicinal Chemistry. 2 (2): 163–75.
doi:
10.2174/1389557024605474.
PMID12370077.
^Hensen C, Hermann JC, Nam K, Ma S, Gao J, Höltje HD (December 2004). "A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors". Journal of Medicinal Chemistry. 47 (27): 6673–80.
doi:
10.1021/jm0497343.
PMID15615516.
Mozenavir (DMP-450) is an
antiviral drug which was developed as a treatment for
HIV/AIDS. It acts as an HIV
protease inhibitor and binds to this target with high affinity,[1][2] however despite promising results in early testing,[3][4] mozenavir was unsuccessful in human
clinical trials. Studies continue into related derivatives.[5]
References
^Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, et al. (May 1996). "Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors". Journal of Medicinal Chemistry. 39 (11): 2156–69.
doi:
10.1021/jm960083n.
PMID8667359.
^Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP (April 1998). "The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues". Bioorganic & Medicinal Chemistry Letters. 8 (7): 823–8.
doi:
10.1016/s0960-894x(98)00119-x.
PMID9871548.
^De Clercq E (April 2002). "Highlights in the development of new antiviral agents". Mini Reviews in Medicinal Chemistry. 2 (2): 163–75.
doi:
10.2174/1389557024605474.
PMID12370077.
^Hensen C, Hermann JC, Nam K, Ma S, Gao J, Höltje HD (December 2004). "A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors". Journal of Medicinal Chemistry. 47 (27): 6673–80.
doi:
10.1021/jm0497343.
PMID15615516.